ANDA 70826, held by Am Regent. Dopamine Hydrochloride.
As of Nov 16, 2026, ANDA 70826 (Dopamine Hydrochloride), held by Am Regent, was first approved by FDA on Feb 11, 1987, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 1987 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dopamine Hydrochloride160MG/ML · injectable;injection | Dopamine Hydrochloride | Discontinued |
| Jun 21, 2021 | Supplement 16Labeling · Standard review | Approved | None posted |
| Nov 7, 2001 | Supplement 10Labeling | Approved | None posted |
| Jan 7, 1998 | Supplement 8Manufacturing | Approved | None posted |
| Nov 7, 1997 | Supplement 9Labeling | Approved | None posted |
| Sep 24, 1996 | Supplement 7Labeling | Approved | None posted |
| Feb 28, 1996 | Supplement 6Manufacturing | Approved | None posted |
| Jun 30, 1993 | Supplement 5Manufacturing | Approved | None posted |
| Oct 27, 1992 | Supplement 4Labeling | Approved | None posted |
| Aug 26, 1992 | Supplement 3Labeling | Approved | None posted |
| Feb 5, 1992 | Supplement 2Manufacturing | Approved | None posted |
| Jun 30, 1989 | Supplement 1Manufacturing | Approved | None posted |
| Feb 11, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters